Chahua Huang1,2, Yang Liu3, Andrew Beenken3, Lin Jiang4, Xiang Gao4, Zhifeng Huang5, Anna Hsu6, Garrett J Gross6, Yi-Gang Wang4, Moosa Mohammadi3, Jo El J Schultz1. 1. Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA. 2. Department of Cardiology, Second Affiliated Hospital, Nanchang University, Nanchang 330006, China. 3. Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA. 4. Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA. 5. School of Pharmacy and Center for Structural Biology, Wenzhou Medical University, Zhejiang 325035, China. 6. Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Abstract
AIMS: Fibroblast growth factor 1 (FGF1), a heparin/heparan sulfate-binding growth factor, is a potent cardioprotective agent against myocardial infarction (MI). The impact of heparin, the standard of care for MI patients entering the emergency room, on cardioprotective effects of FGF1 is unknown, however. METHODS AND RESULTS: To address this, a rat model of MI was employed to compare cardioprotective potentials (lower infarct size and improve post-ischemic function) of native FGF1 and an engineered FGF1 (FGF1ΔHBS) with reduced heparin-binding affinity when given at the onset of reperfusion in the absence or presence of heparin. FGF1 and FGF1ΔHBS did not alter heparin's anticoagulant properties. Treatment with heparin alone or native FGF1 significantly reduced infarct size compared to saline (P < 0.05). Surprisingly, treatment with FGF1ΔHBS markedly lowered infarct size compared to FGF1 (P < 0.05). Both native and modified FGF1 restored contractile and relaxation function (P < 0.05 versus saline or heparin). Furthermore, FGF1ΔHBS had greater improvement in cardiac function compared to FGF1 (P < 0.05). Heparin negatively impacted the cardioprotective effects (infarct size, post-ischemic recovery of function) of FGF1 (P < 0.05) but not of FGF1ΔHBS. Heparin also reduced the biodistribution of FGF1, but not FGF1ΔHBS, to the left ventricle. FGF1 and FGF1ΔHBS bound and triggered FGFR1-induced downstream activation of ERK1/2 (P < 0.05); yet, heparin co-treatment decreased FGF1-produced ERK1/2 activation, but not that activated by FGF1ΔHBS. CONCLUSION: These findings demonstrate that modification of the heparin-binding region of FGF1 significantly improves the cardioprotective efficacy, even in the presence of heparin, identifying a novel FGF ligand available for therapeutic use in ischemic heart disease. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Fibroblast growth factor 1 (FGF1), a heparin/heparan sulfate-binding growth factor, is a potent cardioprotective agent against myocardial infarction (MI). The impact of heparin, the standard of care for MI patients entering the emergency room, on cardioprotective effects of FGF1 is unknown, however. METHODS AND RESULTS: To address this, a rat model of MI was employed to compare cardioprotective potentials (lower infarct size and improve post-ischemic function) of native FGF1 and an engineered FGF1 (FGF1ΔHBS) with reduced heparin-binding affinity when given at the onset of reperfusion in the absence or presence of heparin. FGF1 and FGF1ΔHBS did not alter heparin's anticoagulant properties. Treatment with heparin alone or native FGF1 significantly reduced infarct size compared to saline (P < 0.05). Surprisingly, treatment with FGF1ΔHBS markedly lowered infarct size compared to FGF1 (P < 0.05). Both native and modified FGF1 restored contractile and relaxation function (P < 0.05 versus saline or heparin). Furthermore, FGF1ΔHBS had greater improvement in cardiac function compared to FGF1 (P < 0.05). Heparin negatively impacted the cardioprotective effects (infarct size, post-ischemic recovery of function) of FGF1 (P < 0.05) but not of FGF1ΔHBS. Heparin also reduced the biodistribution of FGF1, but not FGF1ΔHBS, to the left ventricle. FGF1 and FGF1ΔHBS bound and triggered FGFR1-induced downstream activation of ERK1/2 (P < 0.05); yet, heparin co-treatment decreased FGF1-produced ERK1/2 activation, but not that activated by FGF1ΔHBS. CONCLUSION: These findings demonstrate that modification of the heparin-binding region of FGF1 significantly improves the cardioprotective efficacy, even in the presence of heparin, identifying a novel FGF ligand available for therapeutic use in ischemic heart disease. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith Journal: Circulation Date: 2011-03-28 Impact factor: 29.690
Authors: M F Flanagan; T Aoyagi; L W Arnold; C Maute; A M Fujii; J Currier; D Bergau; H B Warren; K Rakusan Journal: Circulation Date: 1999-08-31 Impact factor: 29.690
Authors: Alexandra Buehler; Alessandra Martire; Claudia Strohm; Swen Wolfram; Borja Fernandez; Meindert Palmen; Xander H T Wehrens; Pieter A Doevendans; Wolfgang M Franz; Wolfgang Schaper; René Zimmermann Journal: Cardiovasc Res Date: 2002-09 Impact factor: 10.787
Authors: M Mohammadi; A M Honegger; D Rotin; R Fischer; F Bellot; W Li; C A Dionne; M Jaye; M Rubinstein; J Schlessinger Journal: Mol Cell Biol Date: 1991-10 Impact factor: 4.272
Authors: Virginia Campani; Iris Chiara Salaroglio; Valeria Nele; Joanna Kopecka; Andreas Bernkop-Schnürch; Chiara Riganti; Giuseppe De Rosa Journal: Pharmaceutics Date: 2022-01-26 Impact factor: 6.321
Authors: Guoqi Li; Yihui Shao; Hong Chang Guo; Ying Zhi; Bokang Qiao; Ke Ma; Jie Du; Yong Qiang Lai; Yulin Li Journal: Cardiovasc Res Date: 2022-07-20 Impact factor: 13.081